CDYL

Across TCGA pan-cancer cohorts, CDYL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDYL data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CDYL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDYL expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where CDYL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	23	view →
PDAC	OS	Quartile	All	0.283	0.651	.007	14	view →
LSCC	OS	Median	II,III,IV	1.000	0.886	.022	5	view →
UCEC	DFS	Tertile	All	0.830	0.956	.030	2	view →
LUAD	DFS	Median	III,IV	0.709	0.285	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDYL–CCRCC (DFS)

Open the CCRCC breakdown →